Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera

被引:22
作者
Batra, Gaurav [1 ]
Nemani, Satish K. [1 ]
Tyagi, Poornima [1 ]
Swaminathan, Sathyamangalam [1 ]
Khanna, Navin [1 ]
机构
[1] Int Ctr Genet Engn & Biotechnol, Recombinant Gene Prod Grp, New Delhi, India
关键词
SEROTYPE-4; PROTEIN;
D O I
10.1186/1471-2334-11-64
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Flavivirus cross-reactive antibodies in human sera interfere with the definitive identification of dengue virus (DENV) infections especially in areas with multiple co-circulating flaviviruses. Use of DENV envelope domain-III (EDIII) can partially resolve the problem. This study has examined the effect of (i) incorporating the EDIIIs of four DENV serotypes into a single chimeric antigen, and (ii) immobilizing the antigen through specific interaction on the sensitivity and specificity of anti-DENV antibody detection. Methods: A sera panel (n = 164) was assembled and characterized using commercial kits for infection by DENV and a host of other pathogens. Anti-DENV antibodies of both IgM and IgG classes in this panel were detected in indirect ELISAs using a mixture of monovalent EDIIIs, a chimeric EDIII-based tetravalent antigen, EDIII-T, and a biotinylated version of the latter as coating antigens. The sensitivity and specificity of these assays were compared to those obtained using the PanBio Dengue IgG/IgM ELISAs. Results: The performance of dengue IgG and IgM indirect ELISAs, using either a physical mixture of four EDIIIs or the single chimeric EDIII-T antigen, were comparable. Coating of a biotinylated version of the tetravalent antigen on streptavidin plates enhanced sensitivity without compromising specificity. Conclusions: The incorporation of the EDIIIs of the four DENV serotypes into a single chimeric antigen did not adversely affect assay outcome in indirect ELISAs. Oriented, rather than random, immobilization of the tetravalent antigen enhanced sensitivity of detection of anti-DENV antibodies with retention of 100% specificity.
引用
收藏
页数:6
相关论文
共 13 条
[1]   Expression, purification and characterization of in vivo biotinylated dengue virus envelope domain III based tetravalent antigen [J].
Batra, Gaurav ;
Talha, Sheikh Mohd. ;
Nemani, Satish Kumar ;
Dhar, Nisha ;
Swaminathan, Sathyamangalam ;
Khanna, Navin .
PROTEIN EXPRESSION AND PURIFICATION, 2010, 74 (01) :99-105
[2]   Solid supports in enzyme-linked immunosorbent assay and other solid-phase immunoassays [J].
Butler, JE .
METHODS-A COMPANION TO METHODS IN ENZYMOLOGY, 2000, 22 (01) :4-23
[3]  
Gubler D.J., 2007, FIELDS VIROLOGY, V5th, P1153
[4]  
Guzman MG, 2010, EXPERT REV VACCINES, V9, P137, DOI [10.1586/erv.09.139, 10.1586/ERV.09.139]
[5]   Single antigen detects both immunoglobulin M (IgM) and IgG antibodies elicited by all four dengue virus serotypes [J].
Hapugoda, Menaka D. ;
Batra, Gaurav ;
Abeyewickreme, W. ;
Swaminathan, S. ;
Khanna, N. .
CLINICAL AND VACCINE IMMUNOLOGY, 2007, 14 (11) :1505-1514
[6]   Evaluation of Commercially Available Anti-Dengue Virus Immunoglobulin M Tests [J].
Hunsperger, Elizabeth A. ;
Yoksan, Sutee ;
Buchy, Philippe ;
Nguyen, Vinh Chau ;
Sekaran, Shamala D. ;
Enria, Delia A. ;
Pelegrino, Jose L. ;
Vazquez, Susana ;
Artsob, Harvey ;
Drebot, Michael ;
Gubler, Duane J. ;
Halstead, Scott B. ;
Guzman, Maria G. ;
Margolis, Harold S. ;
Nathanson, Carl-Michael ;
Lic, Nidia R. Rizzo ;
Bessoff, Kovi E. ;
Kliks, Srisakul ;
Peeling, Rosanna W. .
EMERGING INFECTIOUS DISEASES, 2009, 15 (03) :436-440
[7]   Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes [J].
Khanam, S ;
Etemad, B ;
Khanna, N ;
Swaminathan, S .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2006, 74 (02) :266-277
[8]   Serological differentiation of infections with dengue virus serotypes 1 to 4 by using recombinant antigens [J].
Ludolfs, D ;
Schilling, S ;
Altenschmidt, J ;
Schmitz, H .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (11) :4317-4320
[9]  
Nakanishi Kazuhiro, 2008, Current Proteomics, V5, P161, DOI 10.2174/157016408785909622
[10]   Avidin and streptavidin in clinical diagnostics [J].
Schetters, H .
BIOMOLECULAR ENGINEERING, 1999, 16 (1-4) :73-78